EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions

Silvia Mara Baez Rodriguez, Ligia Gabriela Tataranu iD, Amira Kamel iD, Serban Turliuc iD, Radu Eugen Rizea iD, Anica Dricu iD

International Journal of Molecular Sciences · 07.10.2024 · 25 (19) · 10765

DOI: 10.3390/ijms251910765 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.10.2024. Verfasst von Silvia Mara Baez Rodriguez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania. Hauptthemen laut MEDLINE: Glioblastoma, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma is known to be one of the most aggressive and fatal human cancers, with a poor prognosis and resistance to standard treatments. In the last few years, many solid tumor treatments have been revolutionized with the help of immunotherapy. However, this type of treatment has failed to improve the results in glioblastoma patients. Effective immunotherapeutic strategies may be developed after understanding how glioblastoma achieves tumor-mediated immune suppression in both local and systemic landscapes. Biomarkers may help identify patients most likely to benefit from this type of treatment. In this review, we discuss the use of immunotherapy in glioblastoma, with an emphasis on immune checkpoint inhibitors and the factors that influence clinical response. A Pubmed data search was performed for all existing information regarding immune checkpoint inhibitors used for the treatment of glioblastoma. All data evaluating the ongoing clinical trials involving the use of ICIs either as monotherapy or in combination with other drugs was compiled and analyzed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmune Checkpoint InhibitorsImmunotherapyHumansBrain NeoplasmsBiomarkers, Tumor

Stichwörter der Autor:innen

blood-brain barrierglioblastomaimmune checkpoint inhibitorsimmunosuppressiontumor microenvironment

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania.
  • Neurosurgical Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.
  • Medical Department, University of Medicine and Pharmacy "G. T. Popa", 700115 Iasi, Romania.
  • Biochemistry Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.

ORCID-Profile: Ligia Gabriela Tataranu, Amira Kamel, Serban Turliuc, Radu Eugen Rizea, Anica Dricu

Zitieren

APA

Rodriguez, S. M. B., Tataranu, L. G., Kamel, A., Turliuc, S., Rizea, R. E., & Dricu, A. (2024). Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions. International Journal of Molecular Sciences, 25(19), 10765. https://doi.org/10.3390/ijms251910765

Vancouver

Rodriguez SMB, Tataranu LG, Kamel A, Turliuc S, Rizea RE, Dricu A. Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions. International Journal of Molecular Sciences. 2024;25(19):10765. doi:10.3390/ijms251910765

BibTeX
@article{Rodriguez2024,
  author = {Rodriguez, Silvia Mara Baez and Tataranu, Ligia Gabriela and Kamel, Amira and Turliuc, Serban and Rizea, Radu Eugen and Dricu, Anica},
  title = {Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {19},
  pages = {10765},
  doi = {10.3390/ijms251910765}
}
Kostenlos starten →